FORM OF WARRANT] Adamis Pharmaceuticals Corporation Warrant To Purchase Common StockAdamis Pharmaceuticals Corp • August 1st, 2019 • Pharmaceutical preparations • New York
Adamis Pharmaceuticals Corporation, a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined in Section 1(b) below) then in effect, at any time or times on or after the Issuance Date (the “Exercisability Date”), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined in Section 16 below), ______________ (_____________)1 fully paid non-assessable shares of Common Stock (as defined in Section 16 below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replaceme
12,000,000 Shares Adamis Pharmaceuticals Corporation Common Stock And Warrants to Purchase up to 12,000,000 Shares of Common Stock* UNDERWRITING AGREEMENTUnderwriting Agreement • August 1st, 2019 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • New York
Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 12,000,000 shares (the “Firm Shares”) of its Common Stock, par value $0.0001 per share (the “Common Stock”) and (ii) warrants to purchase up to an aggregate of 12,000,000 shares of Common Stock on the terms and conditions set forth in the form of warrant attached as Exhibit A hereto (the “Firm Warrants,” and together with the Firm Shares, the “Firm Securities”). All of the Firm Securities are to be issued and sold by the Company. The respective amounts of the Firm Securities to be purchased by each of the several Underwriters are set forth on Schedule I hereto. In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional (i) 1,800,000 shares of Common Stock (the “Additional
